News

Rockefeller Saliva Test for COVID-19 Outperforms Commercial Swab Tests

New study confirms that Darnell’s test performs as well, if not better, than FDA-authorized nasal and oral swab tests

Brought to you byThe Rockefeller University
| 3 min read
Stored in orange-capped vials for mass distribution, the DRUL buffer is part of an inexpensive saliva-based COVID test developed at Rockefeller.
Register for free to listen to this article
Listen with Speechify
0:00
3:00

In the early days of the pandemic, with commercial COVID-19 tests in short supply, Rockefeller’s Robert B. Darnell developed an in-house assay to identify positive cases within the Rockefeller community. It turned out to be easier and safer to administer than the tests available at the time, and it has been used tens of thousands of times over the past nine months to identify and isolate infected individuals working on the university’s campus.

Now, a new study in PLoS confirms that Darnell’s test performs as well, if not better, than FDA-authorized nasal and oral swab tests. In a direct head-to-head comparison of 162 individuals who received both Rockefeller’s “DRUL” saliva test and a conventional swab test, DRUL caught all of the cases that the swabs identified as positive—plus four positive cases that the swabs missed entirely.

To continue reading this article, sign up for FREE
Today's Clinical Lab Logo
Membership is FREE and provides you with instant access to eNewsletters, digital publications, article archives, and more.
Unlock for FREE
Add Today's Clinical Lab as a preferred source on Google

Add Today's Clinical Lab as a preferred Google source to see more of our trusted coverage.

Related Topics